P/E Ratio (TTM): The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM): A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization: Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding: Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float: The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield: A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

P/E Ratio (TTM)
N/A
EPS (TTM)
N/A
Market Cap
^$173.27 M
Shares Outstanding
11.78 M
Public Float
3.32 M
Yield
AKTX has not issued dividends in more than 1 year.
Latest Dividend
N/A
Ex-Dividend Date
N/A

Shares Sold Short: The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last: Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float: Total short positions relative to the number of shares available to trade.

Short Interest (04/29/16)

Shares Sold Short
24,575
Change from Last
-5.53%
Percent of Float
0.74%

Money Flow Uptick/Downtick Ratio: Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

Competitors AKTX

Company	Change	P/E (TTM)
SCMP Sucampo Pharmaceuticals Inc. Cl A	+0.78% +0.09	23.54
LLY Eli Lilly & Co.	-0.65% -0.49	34.67
PFE Pfizer Inc.	+0.23% +0.08	25.02
GWPH GW Pharmaceuticals PLC ADR	+1.12% +0.95	-

More information on AKTX
Competitor Data Provided By: capital cube

Profile AKTX

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded in 2005 and is headquartered in London,...

75/76 Wimpole Street
London Greater London W1G 8LY
United Kingdom

Website
Map

Employees 5

Sector Biotechnology
Sales or Revenue -

Industry Health Care/Life Sciences
1Y Sales Change -

Fiscal Year Ends December 31 Download Reports

Raymond Prudo Executive Chairman

Gur A. Roshwalb CEO, Director, Head-Investor & Media Relations

Clive Richardson Chief Operating Officer & Director

Dov S. Elefant Chief Financial Officer

Research & Ratings Akari Therapeutics PLC ADRAKTX

Per-Share Earnings, Actuals and Estimates

AKTX will report Q1 earnings on false

Actual Analyst Range Consensus

0.50 0.00 -0.50 -1.00

N/A	N/A	N/A	N/A		-0.27	-1.01
Q12015	Q2	Q3	Q4		Q12016	Q2

Q1 2016 Estimate Trends
Current:	^$-0.27
1 month ago:	^$-
3 months ago:	^$-

Q2 2016 Estimate Trends
Current:	^$-1.01
1 month ago:	^$-
3 months ago:	^$-

FY 2016 Estimate Trends
Current:	^$-3.21
1 month ago:	^$-
3 months ago:	^$-

FY 2017 Estimate Trends
Current:	^$-3.64
1 month ago:	^$-
3 months ago:	^$-

Financials Akari Therapeutics PLC ADRAKTX

Net Income

0 200M

0 -200M

Sep 2013 Dec 2013 Mar 2015 Jun 2015 Sep 2015

Sep 2015

5-quarter trend

Net Income Growth

Sales or Revenue

Sales or Revenue Growth

EBITDA

-4.05 M

Overview

Notes & Data Providers

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Sections

My Journal

Akari Therapeutics PLC ADR AKTX (U.S.: Nasdaq)

AT CLOSE 4:00 PM EDT 05/20/16

Volume 0

News Akari Therapeutics PLC ADRAKTX

Key Stock Data

P/E Ratio (TTM)

EPS (TTM)

Market Cap

Shares Outstanding

Public Float

Yield

Latest Dividend

Ex-Dividend Date

Short Interest (04/29/16)

Shares Sold Short

Change from Last

Percent of Float

Stock Money Flow

Competitors AKTX

SCMP

Sucampo Pharmaceuticals Inc. Cl A

LLY

Eli Lilly & Co.

PFE

Pfizer Inc.

GWPH